1-[4-(1H-吲哚-3-基)哌啶基]-1-乙酮 | 30030-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-[4-(1H-吲哚-3-基)哌啶基]-1-乙酮
• 中文别名: 1-[4-(1H-吲哚-3-基)哌啶]-1-乙酮
• 英文名称: 1-<4-(1H-indol-3-yl)piperidino>ethanone
• 英文别名: 1-(4-(1H-indol-3-yl)piperidin-1-yl)ethan-1-one；1-acetyl-4-indol-3-yl-piperidine；1-[4-(1H-indol-3-yl)-piperidine-1-yl]-ethanone；3-(1-acetyl-4-piperidinyl)-1H-indole；3-(1-acetyl-4-piperidyl)indole；3-(N-Acetyl-4-piperidyl)-indol；1-[4-(1H-indol-3-yl)piperidino]ethan-1-one；1-[4-(1H-indol-3-yl)piperidin-1-yl]ethanone
• CAS: 30030-83-2
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.321
• InChiKey: PRFIVCWVSORYRV-UHFFFAOYSA-N

物化性质

• 熔点：
  174 °C
• 沸点：
  476.0±38.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微，加热），甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 储存条件：
  存储条件：2-8°C，密封，干燥

SDS

Name:	1-[4-(1H-Indol-3-yl)piperidino]ethan-1-one 97% Material Safety Data Sheet
Synonym:
CAS:	30030-83-2

Section 1 - Chemical Product MSDS Name:1-[4-(1H-Indol-3-yl)piperidino]ethan-1-one 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
30030-83-2	1-[4-(1H-Indol-3-yl)piperidino]ethan-1	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 30030-83-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 174 - 176 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H18N2O
Molecular Weight: 242.32

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 30030-83-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-[4-(1H-Indol-3-yl)piperidino]ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 30030-83-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 30030-83-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 30030-83-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[4-(1H-吲哚-3-基)哌啶基]-1-乙酮 在 sodium hydroxide 、 碳酸氢钠 、 potassium carbonate 、 sodium iodide 、 copper(II) oxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.0h， 生成 4-[4-(1-Phenyl-3-indolyl)piperidinomethyl]-2-acetylaminothiazole
  参考文献：
  名称：

  Synthesis and Structure-Activity Relationships of Antiallergic N-(4-(4-(1H-Indol-3-yl)piperidinoalkyl)-2-thiazolyl)alkanamides Possessing Both Antihistaminic and Anti Slow-Reacting Substance (SRS) Activities.

  摘要：

  合成了一系列N-[4-[4-(1H-吲哚-3-基)哌啶醇烷基]-2-噻唑基]烷酰胺衍生物，并测试了其体内抗过敏反应活性和体外抗缓慢反应物质(SRS)活性。在合成的化合物中，N-[4-[4-(1H-吲哚-3-基)哌啶甲基]-2-噻唑基]丙酰胺(7)是平衡性最佳的化合物（抗过敏反应活性，ED50=0.92mg/kg 口服；抗SRS活性，IC50=0.89μg/ml）。关于7的生物活性，我们将抗过敏反应活性归因于其强效的抗组胺活性，而将抗SRS活性归因于对5-脂氧合酶的抑制。

  DOI：

  10.1248/cpb.42.1822
• 作为产物：
  描述：

  N-苄基哌啶酮 在 palladium 10% on activated carbon 、 氢气 、 碳酸氢钠 、 溶剂黄146 、 potassium hydroxide 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 、 异丙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 6.17h， 生成 1-[4-(1H-吲哚-3-基)哌啶基]-1-乙酮
  参考文献：
  名称：

  Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype

  摘要：

  A series of 3-piperidin-4-yl-1H-indoles with building block diversity was synthesized based on a hit derived from an HTS whole-cell screen against Plasmodium falciparum. Thirty-eight compounds were obtained following a three-step synthetic approach and evaluated for anti-parasitic activity. The SAR shows that 3-piperidin-4-yl-1H-indole is intolerant to most N-piperidinyl modifications. Nevertheless, we were able to identify a new compound (10d) with lead-like properties (MW = 305; cLogP = 2.42), showing antimalarial activity against drug-resistant and sensitive strains (EC50 values similar to 3 mu M), selectivity for malaria parasite and no cross-resistance with chloroquine, thus representing a potential new chemotype for further optimization towards novel and affordable antimalarial drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.047

文献信息

• [EN] ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA<br/>[FR] DERIVES DE PIPERIDINE-ARYLE SERVANT D'INDUCTEURS DE L'EXPRESSION DU RECEPTEUR LDL POUR LE TRAITEMENT DE L'HYPERCHOLESTEROLEMIE
  申请人：GLAXO GROUP LTD

  公开号：WO2004006922A1

  公开（公告）日：2004-01-22

  This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.

  这项发明涉及一种新型化合物，可以上调LDL受体（LDL-r）的表达，并涉及其制备过程、含有它们的药物组合物以及它们的医疗用途。更具体地，这项发明涉及式（I）的新型芳香基哌啶及其在治疗中的应用。
• [EN] ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA<br/>[FR] DERIVES D'ARYLE PIPERIDINE SERVANT D'INDUCTEURS DE L'EXPRESSION DU RECEPTEUR LDL POUR LE TRAITEMENT DE L'HYPERCHOLESTEROLEMIE
  申请人：GLAXO GROUP LTD

  公开号：WO2004007493A1

  公开（公告）日：2004-01-22

  This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy. wherein Ar1is substituted by at least one R' group selected from: -O(CRaRb)nC(O)NRxRy,. -O(CH2)nCN, -O(CH2)nO(CH2)mOR2, -O(CH2)nCO2R2, -OSO2NRXRy, -OSO2(CH2)pCH3, -(CRaRb)nC(O)NRXRy, -(CH2)nCN, -(CH2)nO(CH2)mOR2, -(CH2)nCO2R2, -(CH2)nC(O)R2, - SO2NRXRy, -SO2(CH2)pCH3, -CH=CHC(O)NRxRy, -CH=CHCN, -CH=CHCO2R2, -CO2R2 , - C(O)R2, -C(O)NRXRy and C2-5alkenyl; and Ar2 is substituted by 1-4 groups independently selected from the group consisting of: (CH2)nOH and -C02(CH2)pCH3.

  这项发明涉及促进低密度脂蛋白受体（LDL-r）表达的新化合物，以及它们的制备方法、含有它们的药物组合物和它们的医疗用途。更具体地说，这项发明涉及式（I）的新芳香哌啶类化合物及其在治疗中的应用。其中Ar1被至少一个R'基取代，所述R'基选自以下基团之一：-O(CRaRb)nC(O)NRxRy、-O(CH2)nCN、-O(CH2)nO(CH2)mOR2、-O(CH2)nCO2R2、-OSO2NRXRy、-OSO2(CH2)pCH3、-(CRaRb)nC(O)NRXRy、-(CH2)nCN、-(CH2)nO(CH2)mOR2、-(CH2)nCO2R2、-(CH2)nC(O)R2、-SO2NRXRy、-SO2(CH2)pCH3、-CH=CHC(O)NRxRy、-CH=CHCN、-CH=CHCO2R2、-CO2R2、-C(O)R2、-C(O)NRXRy和C2-5烯基；Ar2被独立选择的1-4个基团取代，所述基团选自(CH2)nOH和-C02(CH2)pCH3。
• Synthesis and Pharmacological Properties of N-[4-[4-(1H-Indol-3-yl)-piperidinoalkyl]-2-thiazolyl]alkanesulfonamides as Novel Antiallergic Agents.
  作者：Shinji SHIGENAGA、Takashi MANABE、Hiroshi MATSUDA、Takashi FUJII、Jun HIROI、Masaaki MATSUO

  DOI：10.1248/cpb.41.1589

  日期：——

  A number of N-[4-[4-(1H-indol-3-yl)piperidinoalkyl]-2- thiazolyl]alkanesulfonamides (8--21) were synthesized and evaluated for their preventive effects on systemic anaphylaxis in guinea pigs. Structure-activity analysis revealed that methane- and ethanesulfonamide derivatives having a one to three methylene tether between the piperidine and thiazole rings exhibited potent activity but the introduction

  合成了许多N- [4- [4-（1H-吲哚-3-基）哌啶子基烷基] -2-噻唑基]烷磺酰胺（8--21），并评估了它们对豚鼠全身过敏反应的预防作用。结构活性分析表明，在哌啶和噻唑环之间具有1-3个亚甲基醚的甲烷和乙磺酰胺衍生物显示出强活性，但是在吲哚部分引入取代基降低了活性。对小鼠施用（100 mg / kg po）四种化合物8、9、12、13以及酮替芬，奥托米特，特非那定和氮卓斯汀作为参考化合物，对小鼠显示，仅化合物8不会引起由下列药物引起的睡眠时间显着增加己烯比妥。另外，化合物8（10 mg / kg iv）不会改变清醒兔子的脑电图。这些结果导致选择N- [4- [4-（1H-吲哚-3-基）哌啶子甲基] -2-噻唑基]甲磺酰胺（8，FK613）作为新的抗过敏剂进行进一步开发。FK613的临床评估目前正在进行中。
• [EN] INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES<br/>[FR] DERIVES D'INDOLE POUR LE TRAITEMENT DE MALADIES DES OS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005056012A1

  公开（公告）日：2005-06-23

  This invention relates to a method for preventing and/or treating bone diseases which comprises administering a potentiator of TGF-beta activity such as the compound of the formula [I] or pharmaceutically acceptable salts thereof to human being or animals. wherein R1 is hydrogen, etc., R2 is optionally substituted ar(lower)alkyl or optionally substituted heterocyclic(lower)alkyl, etc., R3 is hydrogen, optionally substituted hydroxy, etc., R4 is hydrogen or lower alkyl, and X is CH or N.

  这项发明涉及一种用于预防和/或治疗骨疾病的方法，包括向人类或动物施用TGF-beta活性增强剂，如式[I]的化合物或其药用盐。其中R1是氢，R2是可选择取代的芳基(较低)烷基或可选择取代的杂环(较低)烷基，R3是氢，可选择取代的羟基，R4是氢或较低烷基，X是CH或N。
• Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
  申请人：——

  公开号：US20040077654A1

  公开（公告）日：2004-04-22

  The invention concerns Use of a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof, in the manufacture of a medicament for the treatment of diseases ameliorated by LDL-r upregulation, to novel compounds and pharmaceutical compositions within the scope of formula (I).

  该发明涉及使用式(I)的化合物或其生理上可接受的盐、溶剂合物或衍生物，用于制造治疗通过LDL-r上调改善的疾病的药物，以及在式(I)范围内的新化合物和药物组合物。